Galera schedules type a meeting with fda to discuss next steps for avasopasem

Malvern, pa., sept. 18, 2023 (globe newswire) -- galera therapeutics, inc. (nasdaq: grtx), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that a type a meeting has been scheduled for september 28, 2023 with the u.s. food and drug administration (fda) regarding the complete response letter (crl) received for the company's new drug application (nda) for avasopasem manganese (avasopasem). the fda is expected to issue written meeting minutes approximately 30 days following the meeting.
GRTX Ratings Summary
GRTX Quant Ranking